HOME >> BIOLOGY >> NEWS
New drug enfuvirtide shows promise against drug resistant HIV infection

CHAPEL HILL -- The new drug enfuvirtide, a member of a new class of medications designed to combat HIV -- the virus that causes AIDS -- shows strong promise in treating drug-resistant cases of the life-threatening infection, a study conducted with patients in North and South America concludes.

A report on the research appears in the May 29 issue of the New England Journal of Medicine.

"This is one of the most important studies performed to date in HIV-infected patients who have already received highly active antiretroviral therapy (HAART) and a landmark study for the field of HIV," said Dr. Joseph Eron of the University of North Carolina at Chapel Hill and a report author.

"The clinical work clearly demonstrates that a completely new class of anti-HIV medication, developed by a local company, Trimeris, is highly effective in a very large randomized study," said Eron, associate professor of medicine at the UNC School of Medicine.

"Enfuvirtide, or T-20, works by blocking HIV entry into CD4 + lymphocytes or T-cells and will benefit patients who already have HIV that is resistant to current therapy."

CD4+ lymphocytes, also known as T-cells, are a key part of the body's immune system for fighting off disease-causing viruses, bacteria and various other organisms, he said. HIV is so deadly because it kills those defenders and leaves patients vulnerable to a wide variety of debilitating illnesses.

Fuzeon is enfuvirtide's trade name.

Another report of a second study with similar results carried out in Europe and Australia also appears in the May 29 issue of the journal. Eron and Dr. J. Michael Kilby of the University of Alabama at Birmingham have a third article in the journal describing T-20 and other drugs now in development in the new class of HIV medications called entry inhibitors.

Dr. Jacob P. Lalezari of Quest Clinical Research, Mount Zion Hospital and the University of California at San Francisco led
'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
28-May-2003


Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... , Dec. 8, 2016 Market Research Future published a ... The global Mobile Biometric Security and Service Market is expected to ... 2022. Market Highlights: ... , Mobile Biometric Security ... to the increasing need of authentication and security from unwanted cyber ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... -- The Board of Directors of the Pittsburgh Life ... only pure life sciences investment firm, today announced ... plan developed by the Nominating and Governance Committee over ... F. Jordan is selected to serve as President ... , who is elected to the position of Executive ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 This report ... following Product Segments: Acid Based (Humic, Amino, & Fulvic), Extract ... by the following Crop Types: Ornamental & Turf, Row Crops, ... US, Canada , Japan ... , Latin America , and Rest of ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events ... building events, new program offerings and company expansion. , This is largely ... include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand for ...
(Date:12/8/2016)... SAN DIEGO, Dec. 8, 2016  OncoSec Medical ... company developing DNA-based intratumoral cancer immunotherapies, today announced ... "We are delivering on our ... melanoma with ImmunoPulse® IL-12. We are pleased with ... melanoma combination trial, and we are focused on ...
Breaking Biology Technology:
Cached News: